Diagnóstico Genético Para Enfermedades Neurodegenerativas. Un Importante Desafío Para Chile

Miranda, Caio M. de; Bustamante, Chris

doi:10.1016/j.rmclc.2016.06.007

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent advances in the design of specific biomarkers for brain imaging have improved clinic diagnostics using MRI. These improvements have allowed the characterization of different phenotypes of neurodegenerative disorders by detecting structural and functional changes 6,7 . Current research is oriented to the design of biomarker probes using peptides and antibodies to detect and evaluate, in real-time, modifications, or molecular alterations in cell populations or tissues of interest 8,9 .…”

Section: Introductionmentioning

confidence: 99%

Characterization of Zero-Valent Iron Nanoparticles Functionalized with a Biomarker Peptide

et al. 2021

View full text Add to dashboard Cite

The identification of peptides that can be coupled to magnetic nanoparticles and be directed against specific receptors has been developed and applied intensively in various biomedical applications, such as magnetic resonance imaging (MRI), to diagnose neurodegenerative diseases. This work describes the properties of magnetic zero-valent iron (nZVI) nanoparticles coated with silica and subsequently decorated with a peptide as a biomarker of neuroinflammation. The synthesized nanostructured compounds were systematically characterized by XRD, SEM, AFM, DLS, FTIR and VSM techniques. Biotin-Streptavin-HRP system was carried out to confirm the peptide's anchoring to the surface of the nanoparticles. The results showed that this nanostructured compound is an excellent candidate as a contrast agent capable of being used in magnetic resonance imaging, which would optimize the diagnosis of neuroinflammatory lesions compared to current contrast media.

show abstract